Here are five details:
- The test turns around results in three to five business days.
- The test requires as little as 3 millimeters of tissue.
- The test is highly accurate, using next-generation sequencing and immunohistochemistry.
- The test is easy to interpret with NCCN Compendium-based recommendations.
- A study of a previous generation of the test found an increased rate of progression-free survival compared to patients who didn’t use the test.
“The systemic treatment of patients with advanced or metastatic cancer is challenging,” Exact Sciences CMO of Precision Oncology Rick Baehner, MD, said in a statement. “Oncotype MAP is a tissue-based assay which delivers results regarding the underlying biology of a patient’s cancer and provides therapeutic and clinical trial options. Genomic results guide clinicians to individualize and optimize oncology therapy by targeting patient tumor biology with the most effective therapies.”
Read the full press release here.
More articles on surgery centers:
U of Minnesota opens clinical trial to treat GI cancers with CRISPR engineering
Many colonoscopies end with surprise medical bills, study says
Connecticut hospital opens GI center
